Member Info for Saxondale

100k volume on the Nas - and up a further 9% , yet we didn't see Mr 5k taking any from here today .

The ASH conference and the poster has been common knowledge for months .

So I wonder why the sudden interest and surge so late on . Surely it isn't just people just piling in for a punt ?

Like CB says - still 100% owned - so the whole pie is still ours , as will be the glory and future revenues ( at this moment).

Once the FDA give Faron clear direction of how to proceed to market - expect some fireworks .

Looking good this week . News to come soon .

Our session is on Sunday -

https://ash.confex.com/ash/2023/webprogram/Paper174912.html

so perhaps we will get an RNS with latest updated data sets on Bexmab on Monday ?

Just noticed that Faron actually files 2 patents here , not just one .

The first relates to the method on tumours showing Clever 1 expression.

https://patents.google.com/patent/WO2023222953A1/en?assignee=faron+pharmaceuticals&oq=faron+pharmaceuticals&sort=new

A tumor sample which shows substantial percentage of CLEVER-1 expressing intra-tumoral cells is an indication that the cancer patient is responsive to the anti-CLEVER-1 therapy.

The second looks very similar but relates to the method on tumours where there is a low PDL1 expression or no PDL1 cells , along with higher percentage of Clever1 expression - suggesting a patient will be receptive .

https://patents.google.com/patent/WO2023222952A1/en?assignee=faron+pharmaceuticals&oq=faron+pharmaceuticals&sort=new

A tumor sample which shows low percentage of PD-L1 expressing cells or not comprising PD-L1 expressing cells together with substantial percentage of CLEVER- 1 expressing intra-tumoral cells is an indication that the cancer patient is responsive to the anti-CLEVER-1 therapy.

A small detail - but indicates they are targeting these patients and will all be part of preparations for BEXCOMBO .

16% up over on the Nas - going into the ASH weekend conference - with Markuu excited to reveal the next set of data .

Did anyone else hear Markku talk of the new interim CMO , as someone who knew extensively about the regulatory business of getting accelerated market approvals . Clearly a reason for the switch from MLF I would guess.

I think Nasdaq North was closed yesterday - good to put this out in the lead up to ASH .

interesting interview with the head of ASH this week too - about the importance of new groundbreaking Immunotherapies and targetted treatments for haematological cancers ( ie Bex among others ) .

https://www.youtube.com/watch?v=21erv2hITwE

Https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(23)00501-3

Highlights

•

Targeting Clever-1 with bexmarilimab is well tolerated

•

Disease control in late-stage cancer can be achieved with bexmarilimab monotherapy

•

Low baseline immune activation associates with bexmarilimab benefit

•

Bexmarilimab converts intratumoral macrophages to support adaptive immune responses

New patent also out - detailing the method for patient selection ( in solid tumour situation I'm assuming ).

https://patents.google.com/patent/WO2023222953A1/en?assignee=faron+pharmaceuticals&oq=faron+pharmaceuticals&sort=new

This method requires a sample of the pateint tumour to see if there is any Clever-1 expression . Not read the whole patent yet but it looks like if tumour has a good amount of clever 1 expressing cells , then the patient would liekly respond to the treatment .

A very key element in getting better results and also box ticking for Big Pharma looking to invest .

Another piece of the jigsaw in place .Nice one !

From the blurb

an accurate method has been found for identifying cancer patients that respond to a treatment comprising an administration of an agent capable of binding to CLEVER-1 , preferably anti-CLEVER-1 antibody, more preferably anti- CLEVER-1 antibody bexmarilimab. Especially it has been found an accurate method for pre-treatment identification of cancer patients, which method provides accurate results by machine reading from the stained samples using a specific staining antibody.

Back from a few weeks in the sun to catch up on this very positive interview .

Fully expecting a major partner with resources soon .

Latest data readings look to be as good as expected - coming soon .

Clinical site website also updated - Matins trial now marked as completed - and Bexmab study updated with new US trial sites .

Just need to sit tight now and wait for the good news.

Apologies for my crude attempt at a joke yesterday .

Added again today . I may have missed some of the initial rise , but we are still in the foothills of the real potential SP as Chris build this company up .

I'm comfortable with a longer wait for a deal announcement . He will want to get the best outcome , and there is no need to bite any ones hand off prematurely .

Janus ?

Great update there . Intense discussions , and major relief at cost savings of P2 due to limited numbers allowed by FDA - who seem to be doing all they can to get this drug on the market .

I guess this news wasn't unexpected - but positive all the same , and things look to be gathering pace .

Long way for the SP to climb if and when a deal is done .

I'm not an expert so its just my opinion - but it seems they are running a P2 just on MDS ( which was giving the best data in P1) with existing funds .

I remember Markku answering a question about partners a while back , and he said something along the lines of ' maybe a partner will want to see a P2 before committing'

I'm pretty sure also that you don't start a trial unless you have funding in place to complete it .

I don't think they will fund a P3 alone - but then again their discussions with FDA may throw up some kind of accelerated route .

I believe this is just the start of the news flow .

Should be a fairly quick P2 trial - only 32 patients , and a review after 20 .

Looks like they have funds to complete it alone then .

I guess much of the cost of these trials is front loaded , so now its running we could get a P2 readout whilst being 100% wholly owned .

Focusing on MDS in P2 . I wonder if they will also have an AML arm ?

Expect P1 data readout next .

New US sites coming online .

All good .

I like the title - but come on Faron - give us a bit more info lol !

Bexmarilimab activates human tumor-associated macrophages to support adaptive immune responses in interferon-poor immune microenvironments

https://aacrjournals.org/cancerimmunolres/article/doi/10.1158/2326-6066.CIR-23-0350/730008/Bexmarilimab-activates-human-tumor-associated

Well , I just about got my top up at the placing price this morning .

Sp has settled down while we wait for the next price of news .

Faron now clear to progress their plans into next year .

The upcoming ASH poster involves Naval Daver - our enthusiastic and influential man at MD Anderson .

LLS have also recently announced that they are increasing the amount that they will be funding research programs in 2024 .

And I re-read the RNS about what they planned to do with the 7.1 million euros.

Onwards and upwards .

Should the Company raise approximately EUR 6.0 million, the Company would have sufficient funding for its working capital needs into Q1 2024. The Company intends to use the proceeds of the Placing for the following:

· BEXMAB program (approx. 29%)

· Initiation of Phase 2

· Opening 5 new sites in the US

· Full Phase 1 data readout

· Bexmarilimab CMC (approx. 38%)

· First commercial scale production batch of Bex (2000 L)

· Other clinical development (approx. 5%)

· G&A (approx. 15%)

· Financing (approx. 13%)

Something old , something new . and look at the share price , it nearly gone blue !

Yes and I could yesterday too , eventually .

I see that as a good sign , not a ramp or anything .

In fact , when I started buying in here a while a go it was similar .

I've got holdings that on most days you can't get a quote to sell , but you can buy as much as you want .

Yep I can't get a quote for even 500 shares.

Similar to this morning .

Whatever the rumour , someone is definitely wanting these shares at the moment .

I had some more this morning , but took a long time to get them.

£59m Mcap - ok, its getting bigger , but still a minnow in these waters .